AGTC To Present At The Stifel 2016 Healthcare Conference On November 15, 2016

GAINESVILLE, Fla. and CAMBRIDGE, Mass., Nov. 03, 2016 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq:AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced that Sue Washer, President and Chief Executive Officer, will present at the Stifel 2016 Healthcare Conference on Tuesday, November 15, 2016 at 3:45pm ET in New York.

A live audio webcast of the presentation can be accessible by visiting ir.agtc.com/events.cfm. A replay will be available on the company's website following the event.

About AGTC

AGTC is a clinical-stage biotechnology company that uses its proprietary gene therapy platform to develop products designed to transform the lives of patients with severe diseases, with an initial focus in ophthalmology. AGTC's lead product candidates are designed to treat inherited orphan diseases of the eye, caused by mutations in single genes that significantly affect visual function and currently lack effective medical treatments.

AGTC's product pipeline includes six named ophthalmology development programs across five targets (X-linked retinoschisis (XLRS), X-linked retinitis pigmentosa (XLRP), achromatopsia, wet age-related macular degeneration and blue cone monochromacy), two non-ophthalmology programs (alpha-1 antitrypsin deficiency and adrenoleukodystrophy) and AGTC is continuing to develop early research studies in additional indications.  The company is also exploring genetic defects in cells in the inner ear that lead to deafness and expects to advance several product candidates into development within the next few years. AGTC employs a highly targeted approach to selecting and designing its product candidates, choosing to develop therapies for indications having high unmet medical need, clinical feasibility and commercial potential. AGTC has a significant intellectual property portfolio and extensive expertise in the design of gene therapy products including capsids, promoters and expression cassettes, as well as, expertise in the formulation, manufacture and physical delivery of gene therapy products.
CONTACT: David Carey (IR) or Danielle Lewis (PR)Lazar Partners Ltd.T: (212) 867-1768 or (212) 843-0211dcarey@lazarpartners.com or dlewis@lazarpartners.comCorporate Contacts:Larry BullockChief Financial OfficerApplied Genetic Technologies CorporationT: (386) 462-2204      lbullock@agtc.comStephen PotterChief Business OfficerApplied Genetic Technologies CorporationT: (617) 413-2754spotter@agtc.com

If you liked this article you might like

These 5 Stocks Are Ready to Break Out

Applied Genetic Technologies Is an Attractive Acquisition Target for Allergan or Biogen

Here's Why Applied Genetic (AGTC) Stock Is Plummeting Today

5 Best-Positioned Biotech Stocks on Brexit Volatility

4 Stocks Spiking on Big Volume